Clinical Trials

Study Title:
A Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

For more information about the trial above please contact the study team:

Principal Investigator, Irl Greenwell, at greenwe@musc.edu, or please call +1 843-792-4759.

Study Coordinator, Sarah Britton, at brittosa@musc.edu, or please call +1 843-792-8856.

Trial opened at the following institutions: Medical University of South Carolina